Argenx has been making significant strides in the biotech sector in recent years. It has earned buy ratings from multiple firms including Oppenheimer, Truist Securities, RBC, BofA Securities, Morgan Stanley, and H.C. Wainwright. These ratings come on the heels of Argenx's positive data from various studies, including a late-stage trial win, resulting in preparations to push
Vyvgart for broader myasthenia gravis population. The company has also reported robust earnings, which have been instrumental in propelling its stock value. Global partnerships have been expanded with FUJIFILM Biotechnologies for production in the US and for a $1.5 Billion collaboration with Unnatural Products to discover macrocyclic peptides. Additionally,
Vyvgart has received FDA approval which is expected to boost sales and drive profitability. Argenx has taken initiative to raise awareness about myasthenia gravis as met with diverse reactions, as the FDA is also considering regulatory action following reports of 'severe worsening' of disease. A potential valuation concern has led to Deutsche Bank downgrading Argenx to 'hold'. Finally, alongside these developments, Argenx has revealed its ARGX-119 Program for ALS, CMS, and SMA treatment, marking a significant breakthrough in Neuromuscular disease.
argenx News Analytics from Wed, 19 Feb 2025 08:00:00 GMT to Tue, 23 Sep 2025 13:40:03 GMT -
Rating 7
- Innovation 8
- Information 7
- Rumor 6
